Is Design Therapeutics Inc (DSGN) overvalued? · $214.0M cap
Design Therapeutics Inc (DSGN) is a biotechnology company listed on US.
This page asks whether Design Therapeutics Inc (DSGN) looks expensive on cached numbers — not a short thesis.
Latest reported DSGN revenue for 2025-09-30 was $0. Net income was -$53.8M. DSGN currently screens at market cap $214.0M.
DSGN currently screens at market cap $214.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DSGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DSGN stock page for the full model, not this heading.
Not investment advice.